01874nas a2200181   4500000000100000008004100001260000900042100001600051700002100067700001800088700002000106700002200126245007400148856006600222490000700288520138300295022001401678       2019                            d  c20191 aGopal Pawar1 aJudith C. Madden1 aDavid Ebbrell1 aJames W. Firman1 aMark T. D. Cronin00aIn Silico Toxicology Data Resources to Support Read-Across and (Q)SAR  uhttps://www.frontiersin.org/articles/10.3389/fphar.2019.005610 v103 aA plethora of databases exist online that can assist in in silico chemical or drug safety assessment. However, a systematic review and grouping of databases, based on purpose and information content, consolidated in a single source, has been lacking. To resolve this issue, this review provides a comprehensive listing of the key in silico data resources relevant to: chemical identity and properties, drug action, toxicology (including nano-material toxicity), exposure, omics, pathways, Absorption, Distribution, Metabolism and Elimination (ADME) properties, clinical trials, pharmacovigilance, patents-related databases, biological (genes, enzymes, proteins, other macromolecules etc.) databases, protein-protein interactions (PPIs), environmental exposure related, and finally databases relating to animal alternatives in support of 3Rs policies. More than nine hundred databases were identified and reviewed against criteria relating to accessibility, data coverage, interoperability or application programming interface (API), appropriate identifiers, types of in vitro, in vivo,-clinical or other data recorded and suitability for modelling, read-across, or similarity searching. This review also specifically addresses the need for solutions for mapping and integration of databases into a common platform for better translatability of preclinical data to clinical data.  a1663-9812